Loading...
•
Dec 31, 2024
Silence Therapeutics Q4 2024 Earnings Report
Silence Therapeutics reported full year financial results and provided a business update.
Key Takeaways
Silence Therapeutics reported its full year 2024 financial results. The company ended the year with over $147 million in cash, cash equivalents and short-term investments and is extending its projected cash runway into 2027 by prioritizing divesiran in PV and programs in rare conditions.
Cash, cash equivalents, and short-term investments were $147.3 million at the end of December 2024.
Collaboration revenue was $43.1 million for the year ended December 31, 2024.
Research and development (R&D) expenses were $67.9 million for the year ended December 31, 2024.
Net loss was $45.3 million for the year ended December 31, 2024.
Silence Therapeutics
Silence Therapeutics
Forward Guidance
Silence announced that it will only initiate the zerlasiran Phase 3 CVOT study once a partner is secured and is extending its projected cash runway into 2027. The Company plans to prioritize development of divesiran in PV and programs in rare conditions with high unmet needs.